FDA warns China’s Xiamen Kang Zhongyuan Biotechnology Co. about producing drugs in insanitary conditions and making misleading or deceptive statements during an agency inspection of its manufacturing facility.
Two pharmacy professors say FDA needs to solicit expert and client input on its new Adverse Event Monitoring System dashboard and use the input to resolve issues with the dashboard.
FDA warns China’s Xiamen Kang Zhongyuan Biotechnology Co. about producing drugs in insanitary conditions and making misleading or deceptive statements during an agency inspection of its manufacturing facility.
Two pharmacy professors say FDA needs to solicit expert and client input on its new Adverse Event Monitoring System dashboard and use the input to resolve issues with the dashboard.
FDA warns the University of California at San Francisco radiopharmaceutical facility about CGMP violations in its production of finished drugs.
FDA warns Par USA/Endo USA about CGMP violations in its manufacturing of finished drugs.
